Intellia Therapeutics, Inc. (NASDAQ:NTLA) Receives $34.95 Average Price Target from Brokerages

Intellia Therapeutics, Inc. (NASDAQ:NTLA - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the twenty-one research firms that are presently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, six have assigned a hold recommendation, thirteen have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $34.95.

A number of analysts have recently commented on the stock. Truist Financial reduced their price target on shares of Intellia Therapeutics from $90.00 to $50.00 and set a "buy" rating for the company in a research note on Tuesday, March 4th. Wedbush reiterated a "neutral" rating and issued a $7.00 price target (down from $10.00) on shares of Intellia Therapeutics in a research note on Thursday, May 29th. Barclays reduced their price target on shares of Intellia Therapeutics from $55.00 to $26.00 and set an "overweight" rating for the company in a research note on Friday, February 28th. JPMorgan Chase & Co. reiterated a "neutral" rating and issued a $13.00 price target (down from $45.00) on shares of Intellia Therapeutics in a research note on Friday, February 28th. Finally, Chardan Capital reiterated a "buy" rating and issued a $68.00 price target on shares of Intellia Therapeutics in a research note on Friday, May 9th.

Hedge Funds Weigh In On Intellia Therapeutics

Several large investors have recently added to or reduced their stakes in NTLA. GF Fund Management CO. LTD. purchased a new position in Intellia Therapeutics during the fourth quarter valued at approximately $25,000. Northwestern Mutual Wealth Management Co. lifted its holdings in shares of Intellia Therapeutics by 56.4% in the first quarter. Northwestern Mutual Wealth Management Co. now owns 4,590 shares of the company's stock worth $33,000 after buying an additional 1,655 shares in the last quarter. Sterling Capital Management LLC lifted its holdings in shares of Intellia Therapeutics by 866.2% in the fourth quarter. Sterling Capital Management LLC now owns 3,198 shares of the company's stock worth $37,000 after buying an additional 2,867 shares in the last quarter. Harbour Investments Inc. lifted its holdings in shares of Intellia Therapeutics by 76.7% in the first quarter. Harbour Investments Inc. now owns 5,214 shares of the company's stock worth $37,000 after buying an additional 2,264 shares in the last quarter. Finally, Whipplewood Advisors LLC purchased a new position in shares of Intellia Therapeutics in the fourth quarter worth $40,000. Hedge funds and other institutional investors own 88.77% of the company's stock.

Intellia Therapeutics Stock Up 6.7%

Intellia Therapeutics stock traded up $0.51 during trading hours on Wednesday, hitting $8.09. The stock had a trading volume of 7,207,575 shares, compared to its average volume of 2,757,291. The stock has a market capitalization of $837.99 million, a P/E ratio of -1.49 and a beta of 2.14. Intellia Therapeutics has a 12-month low of $5.90 and a 12-month high of $28.18. The stock's 50-day moving average price is $7.93 and its 200-day moving average price is $10.06.

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported ($1.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.26) by $0.16. The firm had revenue of $16.63 million during the quarter, compared to analysts' expectations of $11.39 million. During the same period last year, the firm posted ($1.12) earnings per share. The firm's quarterly revenue was down 42.6% on a year-over-year basis. On average, research analysts expect that Intellia Therapeutics will post -5.07 EPS for the current fiscal year.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.